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Summary Growth delay by melphalan of two fibrosarcomas in CBA mice was prolonged by intraperitoneal
(i.p.) verapamil, 10mgkg-1. Verapamil also increased the area under the blood concentration time curve and
the gastrointestinal toxicity of melphalan. Verapamil promoted melphalan cytotoxicity to murine bone
marrow both in vivo, by CFU-S assay, and in vitro, by CFU-GM assay. In Pgml- [14C]-melphalan,
verapamil (1Ougml-1) increased by 1.5 times the [14C]-melphalan accumulation by murine bone marrow,
reversibly and independently of external calcium. Efflux of [14C]-melphalan from murine bone marrow was
retarded by verapamil. Verapamil increased [I4C]-melphalan uptake by disaggregated fibrosarcoma cells but
had no effect on melphalan accumulation and cytotoxicity in human bone marrow. Although verapamil
affected melphalan pharmacokinetics, enhancement of cellular melphalan uptake by verapamil in murine
fibrosarcoma and bone marrow appeared to account for much of the increase in melphalan cytotoxicity. The
lack of potentiation of melphalan by verapamil in human marrow suggests differences in melphalan transport
or in verapamil membrane interactions in mouse and man.
Treatment of tumours is limited by their resistance
to chemotherapeutic drugs, either inherent or
acquired during treatment. Melphalan is widely
used in the treatment of multiple myeloma, ovarian
and breast cancer, and has recently been used in
high intravenous doses in multiple myeloma, acute
leukaemia, solid tumours and paediatric tumours
(Hedley et al., 1978; Pritchard et al., 1982;
Maraninchi et al., 1983; McElwain & Powles,
1983). The dose limiting toxic effects of melphalan
are on the bone marrow, which can be circum-
vented by autologous marrow transplantation
(McElwain et al., 1979), and on the gastrointestinal
tract (Millar et al., 1978b,c). Priming somewhat
ameliorates the toxicity of melphalan (Hedley et al.,
1978; Millar et al., 1978a), but new approaches are
needed to improve the therapeutic index and to
circumvent resistance.
Verapamil is a calcium channel blocker which
reduces excitation-contraction coupling in cardiac
and smooth muscle cells (Fleckenstein, 1977).
Verapamil increases cellular accumulation of vinca
alkaloids and anthracyclines and increases
cytotoxicity in vitro and in vivo in resistant sublines,
and some parent lines, of murine P388 leukaemia,
Lewis lung carcinoma, Ehrlich ascites, human B16
melanoma, colon adenocarcinoma, bladder and
ovarian carcinoma (Tsuruo et al., 1981; 1982; 1983;
Rogan et al., 1984; Slater et al., 1982; Simpson et
al., 1984; Yanovich & Preston, 1984). Resistance to
anthracyclines and vincristine has been associated
with increased active efflux of these drugs (Inaba et
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al., 1981) and with changes in membrane lipid
composition (Ramu et al., 1984); verapamil is
thought to interact with the cell membrane and
decrease active extrusion (Tsuruo et al., 1981;
Kessel & Wilberding, 1984; Murray et al., 1984;
Skovsgaard et al., 1984).
Melphalan is taken into cells by two separate
amino acid transport systems (Goldenberg &
Begleiter, 1980; Vistica, 1983), and efflux occurs
through different undefined pathways. Rogan et al.
(1984) reported that verapamil had no effect on the
cytotoxicity of melphalan in a melphalan-resistant
human ovarian carcinoma cell line. The recent
findings of verapamil potentiation of etoposide-
induced DNA damage and cytotoxicity in L1210
cells in vitro, with decreased etoposide efflux
(Yalowich & Ross, 1984; 1985), and the cross
resistance to melphalan of chinese hamster ovary
cells exhibiting pleiotropic drug resistance (Ling et
al., 1983) suggest that drugs other than anthra-
cyclines and vinca alkaloids may be affected by
verapamil. We here report enhancement of
melphalan-induced growth delay of two murine
fibrosarcomas by verapamil, a finding which
prompted study of the effects of verapamil on
melphalan cytotoxicity and cellular uptake in
murine fibrosarcomas and bone marrow, and in
human bone marrow, and also effects on
pharmacokinetics and normal tissue toxicity in
mice.
Methods
Animals and tumours
Male and female CBA/ca mice, at least 12 weeks
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old were used, and kept at 22°C with free access to
food and water. Two fibrosarcomas, FS12 and
FS13, obtained from Dr S. Eccles, Institute of
Cancer Research (ICR) were passaged every 2-3
weeks as a cell suspension. Tumour was finely
minced with crossed scalpels and incubated at 37°C
in PBS containing 0.5 mgml- pronase,
0.2mgml- 1 DNAse and 0.2mgml-1 collagenase.
The disaggregated tumour cells were washed in PBS
and adjusted to 7 x 106 cellsml-1. Female CBA
mice, 12-24 weeks old, average weight 20g (range
16-24g) were given 0.1ml cell suspension by s.c.
injection into each flank. Experiments were
performed on passages 12-15 of FS12 and 5-12 of
FS13.
Media and drugs
Balanced salt solution (BSS) and PBS were
obtained from the central sterile supplies
department, ICR. PBS and BSS contained no
calcium and no magnesium. Human and mouse
alpha media with 20% newborn calf serum were
used in clonogenic assays.
Melphalan (Alkeran, Burrough's Wellcome, UK)
was dissolved in acid alcohol (5M HCl:ethanol
1:50), 20mgml-1, stored below 0°C, and diluted in
saline immediately before injection. For cell uptake
studies [14C]-melphalan labelled in the chloroethyl
side chain, specific activity 33.7pCimg- 1 (SRI
International), was dissolved in acid alcohol,
I mgml-1, and diluted in PBS to 1 pgml-1 (3.2 pM)
at the start of incubation. For pharmacokinetic
studies, melphalan in acid alcohol was 'spiked'
with [14C]-melphalan. Verapamil hydrochloride
(Cordilox, Abbott) was diluted in saline.
Growth delay
Female CBA mice bearing bilateral s.c. fibro-
sarcomas were divided into groups of 5 mice with
tumours of the same size distribution. On day 0 (2
weeks after transplant), mice were treated with
verapamil 10mgkg-1 i.p., melphalan 10mgkg-'
i.p. or both drugs simultaneously, and a fourth
group were untreated. Tumour volume was
calculated from V=nDd2/6 where D is the longest
diameter and d the perpendicular diameter. Volume
at various times (Vt) was expressed as a ratio of the
volume on day 0 (Vo). The mean+ s.e. of the ratio
(s.e.r.) was calculated for each group.
Pharmacokinetics of[14C-melphalan in mice
The blood levels of [14C]-melphalan after
10mgkg- 1 melphalan i.p. were determined in
groups of 3 CBA mice in the presence and absence
of simultaneous i.p. verapamil in doses of 2.5, 5
and 10mgkg-1. Tail vein blood (20p1) samples
taken over 4h were assayed for `4C, using a
Packard Oxidiser 306 (United Technologies
Packard). In an automatic sequence, 14C was
trapped in 9ml of Carbosorb (Packard) and added
to 13ml of Permafluor V scintillant (Packard).
Samples and dose standards were counted in a
liquid scintillation counter, and ['4C]-melphalan
expressed as a percentage of the dose per ml of
blood. Means+s.e. were compared using the
Student's t test.
Jejunum microcolony assay
Groups of 3 or 4 CBA mice were treated with
melphalan i.p. and/or verapamil 10mgkg-1 i.p. and
killed 4 days later. Three portions of jejunum per
mouse were excised, fixed and 4-5pm thick
transverse sections stained with H&E. Surviving
cryptogenic cells were assessed using a technique
modified from Withers and Elkind (1970) (Millar et
al., 1978b). The number of regenerating crypts per
circumference was expressed as a fraction of the
number of crypts per circumference in untreated
normal mice, and compared as the mean+s.e.r.
using the t test for small samples.
Spleen colony assay
The spleen colony forming cells of mouse bone
marrow (CFU-S) were assayed by the method of
Till and McCulloch (1961). Mice were treated with
i.p. melphalan and/or verapamil and were killed
with control animals one day later for CFU-S
assay. Results of 3 experiments were similar and
were combined.
Clonogenic assay, CFU-GM
The mononuclear fraction of human and mouse
bone marrow was obtained by centrifugation at
400g for 30min over a Ficoll/sodium metrizoate
solution (Lymphoprep, specific gravity 1.077,
Nyegaard). Cells were incubated in the presence of
melphalan (0.01-2pgml-1) and/or verapamil
10pgml-1 at 37°C for 60min, washed and
resuspended in drug-free medium. Then the colony
forming ability of the mononuclear cell fraction
(CFU-GM) was assayed following the method of
Bradley and Metcalf (1966) plating each treatment
group in triplicate. Colony stimulating factor was
derived from pregnant mouse uterus (PMUE) for
mouse marrow, and from 5637 human bladder
carcinoma cells for human marrow (Myers et al.,
1984).
In vitro ['4C]-melphalan uptake and efflux
The mononuclear cell fraction of bone marrow and
disaggregated fibrosarcoma cells, separated from red
cells by centrifugation over Lymphoprep, wereVERAPAMIL POTENTIATION OF MELPHALAN CYTOTOXICITY 815
adjusted to 2-3 x 106 cellsml-' in PBS. No amino
acids were present in the medium (Goldenberg &
Begleiter, 1980; Vistica, 1983). Verapamil (0.1 to
100gm1-1) was added, and finally [14C]-
melphalan, 1 igml 1, and the cells incubated at
37°C for 60min. Then using a method adapted
from Martin et al. (1982), duplicate 1ml aliquots
were layered over 0.5ml oil (mineral oil:silicone oil
(Dow Corning), 1:4) and spun at 12,000g for 2-
3min in a microcentrifuge 320a (Burkard Scientific
Sales Ltd). The cell pellets were solubilised in
Protosol (New England Nuclear) and added to
10ml of ACS scintillant (New England Nuclear)
containing acetic acid 37.5mlgallon-1. Samples
and aliquots of supernatant were counted in a
liquid scintillation counter (Intertechnique). Cell
14C was calculated as ng [14C]-melphalan per 106
cells, and then expressed as a fraction of [14C]-
melphalan in control cells after 60min in
verapamil-free, calcium-free medium. No correction
was made for membrane binding of [14C]-
melphalan, usually <5% of the steady state [14C]-
melphalan level (Goldenberg et al., 1979; Martin et
al., 1982), because plateau levels of [14C]-melphalan
were compared. The results from 2 or more
experiments were combined, as mean±s.e.r.
For [14C]-melphalan efflux studies, cells were
loaded by 30min incubation in 1 ,ugml-' [14C]_
melphalan. Duplicate 1 ml samples were taken (and
spun through oil) and the remaining cells spun
down and resuspended in ice cold medium to
prevent immediate efflux (Goldenberg et al., 1977;
Begleiter et al., 1982; Martin et al., 1982). The cells
were then incubated at 37°C without melphalan, in
the presence or absence of verapamil, with samples
being taken immediately and up to 30min later.
In one experiment, murine bone marrow cells
were incubated 30min at 37°C with [14C]-
melphalan, with or without verapamil. Immediately
after spinning through oil, samples of supernatant
medium and the cell pellets were frozen to stop
melphalan hydrolysis. The cells were ultrasonicated
in 100% methanol and 50 il samples immediately
analysed by high pressure liquid chromatography
(Laboratory Data Control), at absorbance 263nm,
0.001 AUFS sensitivity, using 1:1 methanol:water
with 1% acetic acid solvent (Fisons, HPLC grade)
and 1.4mlmin-1 flow rate, in a method adapted
from Chang et al. (1978). The effluent was collected
in 30 second fractions and counted for 14C, in 10ml
of ACS scintillant. The medium was thawed,
immediately diluted with methanol and analysed
similarly. Verapamil had no effect on the rate of
hyd,rolysis of melphalan in PBS at 370C.
At the beginning and end of each experiment, and
following resuspension, cells were counted using a
Coulter Counter (Coulter Electronics) and viability
determined by trypan blue dye exclusion. Cell size
was determined using a modified Coulter Counter
calibrated with latex particles.
Results
Growth delay ofmurinefibrosarcomas by melphalan:
Effect ofverapamil
The doubling time of FS12 was 5 days. The growth
delay by melphalan 10mgkg-' i.p. was increased
from 6 days to 16 days when verapamil 10mgkg-1
i.p. was also administered (Figure 1). One tumour
from the melphalan group and three from the
melphalan with verapamil group regressed
completely, so the real difference may be greater.
For FS13, verapamil increased the growth delay by
melphalan 10mgkg-t i.p. from 15 days to 22 days
(Data not shown). The fibrosarcoma less sensitive
to melphalan, FS12, showed greater enhancement of
growth delay with verapamil.
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Figure 1 Growth delay of FS12 fibrosarcoma in CBA
mice treated with melphalan 10mgkg-1 i.p. (0) n=9;
verapamil 10mgkg-' i.p. (El) n=8; both (U) n=8; or
untreated (0) n=9. (Mean+s.e.r. of 8-9 tumours;
Vt/Vo is tumour volume as a fraction of volume on
day 0).
Pharmacokinetics of["4C]-melphalan in mice: Effect
ofverapamil
Administration of verapamil 10mgkg-' i.p. with
melphalan 10mgkg-1 i.p. significantly increased
blood ["4C]-melphalan levels and the area under
the curve (Figure 2). A similar increase in blood
[14C]-melphalan levels was seen when melphalan
was given i.v. with verapamil 10mgkg-t i.p. (result
not shown), excluding the possibility that verapamil
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Figure 3 Jejunum microcolonies in CBA mice after
i.p. melphalan, alone (0) or with verapamil
10mgkg-1 i.p. (0). (Mean+s.e.r. of 3-4 mice, 2
separate experiments).
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Figure 2 Blood levels of [14C]-melphalan in CBA
mice treated with [14C]-melphalan 10mgkg- i.p.
alone (0) or with i.p. verapamil (A). (Mean+s.e. of 3
mice).
increased absorption of i.p. melphalan. This
pharmacokinetic effect was still present with
verapamil 5mgkg-1 i.p. but was negligible for
verapamil 2.5mgkg- 1 i.p. (Figure 2).
Normal tissue toxicity ofmelphalan in mice: Effect of
verapamil
The jejunum microcolony assay, performed twice,
showed potentiation of the toxicity of melphalan by
10mgkg-' verapamil i.p. for melphalan doses of
15-20mgkg-' i.p. (Figure 3). In the CFU-S assay
melphalan cytotoxicity to murine bone marrow
stem cells was increased significantly by treatment
with verapamil 10mgkg-1 i.p. but not by the lower
doses of 5 and 2.5mgkg-' i.p. (Figure 4).
Verapamil 10mgkg- 1 i.p. alone had no effect in
either assay. Thus verapamil increased melphalan
toxicity to the two most sensitive normal tissues,
gastrointestinal tract and bone marrow.
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Figure 4 Spleen colonies (CFU-S) in CBA mice after
treatment with i.p. melphalan, alone (0), or with i.p.
verapamil, 2.5 mgkg- I (A), 5mgkg- I (A) or
10mgkg-' (0). (Mean+s.e.r., pooled from 3
experiments).
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Murine and human bone marrow CFU-GM with
melphalan: Effect ofverapamil
The potentiation by verapamil of melphalan-
induced growth delay and of melphalan toxicity
could be due to the pharmacokinetic effect.
However, the following in vitro experiments
suggested that verapamil had a direct effect on
murine bone marrow. When the mononuclear cell
fraction of murine bone marrow was exposed to
melphalan in the presence and absence of verapamil
for 60min, verapamil 10ugml-1 enhanced
melphalan cytotoxicity, approximately two-fold
(Figure 5a). Plating efficiency with PMUE was
1:150-1:200. Verapamil lOpgml-1 had a slight
cytotoxic effect on murine bone marrow which
compares with minimal cytotoxicity of verapamil at
23uM (lO gml-') for P388 cells and at 6.6pM
(3pigml-1) for 4 tumour cell lines (Tsuruo et al.,
1981; 1983).
In contrast, verapamil (lOgml-1) had no effect
on melphalan cytotoxicity to the mononuclear cell
fraction of human bone marrow (Figure Sb). The
plating efficiency of human marrow was 1:700.
Cellular [14C]-melphalan uptake by murine bone
marrow andfibrosarcoma: Effect ofverapamil
Verapamil enhancement of in vitro melphalan
cytotoxicity raised the possibility of an effect on
melphalan uptake, and this was explored in detail.
Accumulation of [14C]-melphalan by the
mononuclear cell fraction of mouse bone marrow
after 60min incubation was greater in the presence
of verapamil (Figure 6) with a 1.5 fold
enhancement at a verapamil concentration of
10pgml-'. Disaggregated fibrosarcoma cells also
accumulated more [14C]-melphalan in the presence
of verapamil 10pgml-1 with a greater effect for
FS12 (Figure 6). Fibrosarcoma FS13 cells,
disaggregated without incubation in enzymes, also
took up 1.22 fold more [14C]-melphalan in the
presence of verapamil 10 ugml-', in 2 experiments,
making it unlikely that the effect was due to
enzymic damage to the cell membrane.
Uptake of [14C]-melphalan was initially rapid,
and reached a plateau after 10-20min for both
murine marrow and fibrosarcoma cells as occurs in
murine L1210 leukaemia cells, L5178Y
lymphoblasts and LPC-1 plasmacytoma cells
(Goldenberg et al., 1977; Martin et al., 1982; Vistica,
1983). For murine bone marrow, cellular [14C]-
melphalan was already 1.4 fold greater in verapamil
treated cells than in controls after 10min (Table I).
The cell volume of mononuclear mouse bone
marrow cells was 0.35,u110-6 cells and the
cell:medium melphalan ratio was 15:1. The viability
of murine bone marrow cells was 90-100% and of
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Figure 5 CFU-GM for murine bone marrow (a) and
human bone marrow (b) after incubation at 37°C for
60min with melphalan, alone (0) or with verapamil
10ggml-1 (). Mean+s.e.r. from 5(a) and 7(b)
experiments.
fibrosarcoma cells 70-85%, and remained constant
within each experiment during the 60min
incubation.
Verapamil's calcium channel blocking action is
overcome by increasing extracellular calcium
concentration (Fleckenstein, 1977). However,
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Figure 6 [14C]-melphalan content of (a) mouse bone
marrow and (b) disaggregated murine fibrosarcoma
cells, incubated 60min at 37°C in 1 pgml-' [14C]_
melphalan, with and without verapamil (0.1-
100pgml-1). (Mean+s.e.r.; number of experiments
shown in the base of each bar).
addition of calcium to the medium had no effect on
[14C]-melphalan uptake, nor on its enhancement by
verapamil 10 ugml-, in murine bone marrow
(Table II). Because high concentrations of calcium
precipitated phosphate when added to PBS, the
second experiment (b) was performed in BSS.
Although addition of melphalan (in acid alcohol) to
BSS lowered pH cell viability was maintained for
the 60min.
Table I Accumulation of [14C]-melphalan by the
mononuclear cell fraction of murine bone marrow,
incubated with lgml-1 [14C]-melphalan at 37°C, with
or without verapamil ljugml -
Duration of Cellular
incubation ['4C]-melphalan ratio: No. of
(min) verapamil/control experiments
10 1.41+0.10 2
30 1.45+0.08 4
60 1.47+0.15 9
(mean+s.e.r.).
Table II ["4C]-melphalan accumulation by murine bone
marrow after 60min in 1 ,igml-1 melphalan, +verapamil
10pgml-1, at 37°C with or without calcium.
(a) Medium Ca
(mM) (in PBS) 0 0.125 0.25
Control 1.00+0.07 1.12+0.07 1.15+0.05
Verapamil 1.50+0.18 1.53+0.10 1.47+0.08
(b) Medium Ca
(mM) (in BSS) 0 1.25 2.50
Control 1.00+0.06 1.02+0.13 1.07+0.06
Verapamil 1.18+0.06 1.46+0.10 1.34+0.06
Uptake as fraction of control without calcium.
Mean+s.e.r. ofduplicates (a) or triplicates (b).
Efflux of["4C]-melphalanfrom murine bone marrow:
Effect ofverapamil
Verapamil appears to decrease extrusion of anthra-
cyclines and vinca alkaloids from resistant cells
(Tsuruo et al., 1981; Skovsgaard et al., 1984) so the
effect of verapamil on melphalan efflux was studied.
When the mononuclear cell fraction of murine bone
marrow, loaded by incubation in [14C]-melphalan
1 pgml-1 for 30min, was resuspended in
melphalan-free medium, the presence of verapamil
(1 and lOpgml-1) retarded loss of ["4C]-melphalan
from the cells (Figure 7). Cell viability was always
90-100%.
This experiment was repeated, using dis-
aggregated murine fibrosarcoma FS13 cells, loaded
with ["4C]-melphalan by 30min incubation at 37°C
in 1 pgml-1. Thirty minutes after resuspension in
melphalan-free medium, with or without verapamil
10 ugml-, cells exposed to verapamil retained
47% of the ['4C]-melphalan present at 30min,
compared with 36% for control cells. Thus it
appears likely that verapamil decreases efflux of
[14C]-melphalan from the fibrosarcoma cells as well.
The following experiment using murine bone
marrow was performed twice, each time with
duplicate samples. When verapamil 10pgml- was
added to cells which had already been incubated in
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Figure 7 Loss of [14C]-melphalan from murine bone
marrow at 37°C in the presence of verapamil Ijgml 1
(V), 10pgml-1 (0) or without verapamil (0).
(Mean+s.e.r. from 5 experiments).
[14C]-melphalan 1 jgml-1 for 30min the [14C]-
melphalan content increased over control values
(lower part of Figure 8). The remainder of the cells
had been incubated in [14C]-melphalan 1 4ugml-I
with verapamil 10igml-1 for 30min and showed
[14C]-melphalan accumulation 1.5 fold greater than
the controls (upper part of Figure 8). However,
these cells lost [14C]-melphalan when they were
spun down and resuspended without verapamil at
37°C in medium of the same [14C]-melphalan
concentration (prepared at time 0 and kept at 37°C
so that hydrolysis would be similar). The [14C]-
melphalan content of cells from which verapamil
was removed approached that of cells never
exposed to verapamil. The lower [14C]-melphalan
content in cells exposed to verapamil after 30min
than in cells incubated with verapamil throughout
is probably due to the presence of less unhydrolysed
melphalan in the medium.
Melphalan hydrolysis in medium and murine bone
marrow cells
The [14C]-melphalan accumulated by murine bone
marrow cells after 30min incubation at 37°C was
separated into hydrolysed and parent drug using
high pressure liquid chromatography and counted
for 14C. Two peaks of radioactivity were identified
corresponding to parent melphalan, and to
hydrolysed drug. Control cells contained 63.3%
unhydrolysed and 29.7% hydrolysed [14C]-
melphalan, while cells exposed to verapamil
contained nearly twice as much melphalan, 72.2%
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Figure 8 [14C]-melphalan content of murine bone
marrow incubated at 37°C in 1 jigml-1 melphalan,
after the addition of verapamil lOpgml-l (C1) to cells
incubated 30min without verapamil (0), and after
centrifugation and resuspension (hatched bar) of cells
with (0) or without (V) verapamil after incubation in
verapamil for the first 30min (Mean+s.e.r. of
duplicates from 2 experiments).
unhydrolysed and 23.9% hydrolysed. After 30min
the control medium contained 68.2% parent
melphalan and 30.2% hydrolysed drug, and the
verapamil-containing medium 67.1% unhydrolysed
and 30.1% hydrolysed drug. At least 93% of [14C]-
melphalan in the cells, and 97% of [14C]-melphalan
in the medium, could be accounted for as parent
compound or hydrolysed drug.
Hydrolysed melphalan is not actively transported
into cells by the transport systems for the
unhydrolysed drug (Goldenberg et al., 1977; 1979;
Begleiter et al., 1979) and it is likely that most of
the [14C]-melphalan enters the cells unhydrolysed,
and then becomes hydrolysed or bound. Verapamil
had no effect on melphalan hydrolysis in the
medium, but appeared to increase uptake of
unhydrolysed melphalan.
Human bone marrow ['4C]-melphalan uptake: Effect
ofverapamil
Medium concentrations of verapamil ranging from
I
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0.1 to lOOygml- had no effect on ["C]-
melphalan accumulation by the mononuclear cell
fraction of human bone marrow (Figure 9), with cell
viability 95-100% throughout. The cell:medium
melphalan ratio was 40:1 in llgml- melphalan,
calculated from a measured cell volume of
0.29p110-6 cells. This compares with a cell volume
of 0.31 pg 10-6 cells and cell:medium ratio of 3:1 in
100pM (31jigml-') melphalan for human
peripheral lymphocytes (Begleiter et al., 1980). Thus,
verapamil had no effect on CFU-GM after
melphalan, nor on cellular [14C]-melphalan uptake,
in human bone marrow.
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Figure 9 [14C]-melphalan content of human bone
marrow incubated 60min at 37°C in 1jlgml-1
melphalan, with and without verapamil (0.1-
100jgml-1). (Mean+s.e.r.; number of experiments
shown at the base of each bar).
Discussion
Treatment with verapamil of CBA mice bearing two
fibrosarcomas potentiated the antitumour effect of
melphalan assessed by growth delay, this effect
being greater in FS12 which was less sensitive to
melphalan. The higher blood levels and greater area
under the curve for melphalan in the presence of
verapamil could have explained both this effect and
the potentiation of bone marrow stem cell and
gastrointestinal toxicity, if it were not for the two-
fold enhancement by verapamil of melphalan
cytotoxicity to murine bone marrow in the in vitro
CFU-GM assay. Verapamil increased murine bone
marrow ['4C]-melphalan accumulation, in a dose-
dependent, reversible way, independent of
extracellular calcium. Verapamil retarded melphalan
efflux from murine bone marrow. Verapamil also
increased ["4C]-melphalan accumulation in dis-
aggregated murine fibrosarcoma tumour cells, and
decreased efflux.
These results suggest that in the murine
fibrosarcomas the cytotoxic effect of melphalan is
potentiated by verapamil, both by a pharmaco-
kinetic effect and an effect on cellular melphalan
accumulation. Other work in our laboratory has
shown no enhancement of blood flow distribution
(determined with 86Rb-rubidium chloride) to the
fibrosarcomas (Robinson et. al., in preparation).
Furthermore, the fractional distribution of cardiac
output after verapamil treatment was increased to
jejunum, decreased to skin and kidney, with no
change in the liver. Thus it is possible that
decreased renal blood flow plays a part in
verapamil's pharmacokinetic effect on melphalan in
mice. Indeed, in man, reduced glomerular filtration
rates are associated with greater marrow toxicity
(Cornwell et al., 1982). Verapamil has been reported
to be therapeutic at blood levels of 0.1-0.3,ugml-1
in man and rats (McMahon & Sheaffer, 1982;
Kaelin et al., 1982), but verapamil is being used in a
clinical trial with adriamycin in ovarian carcinoma
at levels of greater than 1 pgml-1 (Rogan et al.,
1984). Thus the concentrations of 1-10pgml-1 used
here have clinical relevance.
Cellular uptake of [l4C]-melphalan is well
characterised in murine L1210 leukaemia cells,
LPC-1 plasmacytoma cells and L5178Y lympho-
blasts, and is a valid representation offree melphalan
uptake in these cells (Goldenberg et al., 1977,
1979; Martin et al., 1982), and also in murine
bone marrow in our experiments. Active uptake
occurs through two amino acid transport systems,
the L system and the more readily saturable,
sodium-dependent ASC-like system, both of which
are inhibited by physiological concentrations of L-
leucine and L-glutamine (Begleiter et al., 1979;
Goldenberg et al., 1979; Vistica, 1983). Efflux of
melphalan is temperature-dependent but occurs
through different, poorly defined pathways
(Goldenberg et al., 1977; Begleiter et al., 1982). Both
amino acid uptake systems have been identified in
human MCF-7 breast carcinoma cells and
peripheral blood lymphocytes (Begleiter et al.,
1980), but in murine bone marrow progenitor cells,
detected in CFU-GM assay, the sodium-
independent L system is either lacking or has
altered affinity for bicyclic amino acids (Vistica,
1980; Vistica et al., 1983).
In this report, uptake of melphalan was
determined in the mononuclear cell fraction,
including stem cells, progenitor cells (making up at
least 1/200 cells), differentiating and mature cells.
However, the similar enhancement of both
melphalan cytotoxicity to progenitor cells and
melphalan accumulation by mononuclear murineVERAPAMIL POTENTIATION OF MELPHALAN CYTOTOXICITY 821
bone marrow cells suggests that verapamil
enhanced melphalan uptake not only in the CFU-
GM fraction but also in the majority of the other
marrow cells. Verapamil's effect in murine but not
human bone marrow might be related to the much
reduced or absent activity of the L system in
murine bone marrow (Vistica, 1980), for our
experiments do not exclude an additional effect on
influx. However, differences in the cell membrane,
and verapamil's interaction with it, are a more
likely explanation.
Verapamil had no effect on melphalan hydrolysis
in the medium. Both native and hydrolysed
melphalan were increased in murine bone marrow
after verapamil, with a greater proportion
unhydrolysed compared with the medium,
suggesting that verapamil affects transport of
unhydrolysed drug. The effect on melphalan
transport may be a property of all calcium channel
blocking drugs, for preliminary experiments in our
laboratory have shown flunarizine (gift of Janssen
Pharmaceutical) 1 ugmI- 'l-, to enhance [14C]-
melphalan uptake by murine bone marrow 1.4 fold.
The effect of verapamil and anticalmodulin
agents to decrease anthracycline and vincristine
efflux is thought to be mediated either through
intracellular calcium and calcium-dependent enzyme
activities or through interactions with membrane
transport systems (Tsuruo et al., 1981; Beck, 1984;
Kessel & Wilberding, 1984; Skovsgaard et al.,
1984). Here, increasing extracellular calcium did not
prevent verapamil enhancement of melphalan
accumulation in murine bone marrow, consistent
with an effect of verapamil on the membrane
independent of calcium channel blockade.
Melphalan accumulation was reduced in L1210 cells
by vincristine and adriamycin (Martin et al., 1982).
Chinese hamster ovary cells with pleiotropic drug
resistance associated with expression of membrane
P-glycoprotein, induced by anthracyclines or vinca
alkaloids, were resistant to melphalan (Ling et al.,
1983). Furthermore, verapamil reverses pleiotropic
drug resistance (Curt et al., 1984). These findings
suggest that in some cells melphalan transport,
possibly efflux, is linked to transport of anthra-
cyclines, vinca alkaloids and other drugs, and is
susceptible to changes in the membrane.
Some cells resistant to melphalan demonstrate
reduced melphalan accumulation (Redwood &
Colvin, 1980; Vistica, 1983), and it is hoped that
verapamil might enhance melphalan uptake in some
melphalan-resistant tumours in man. The failure of
verapamil to increase melphalan uptake in human
bone marrow would serve to enhance the
therapeutic index of melphalan, but verapamil's
effect on melphalan pharmacokinetics and gastro-
intestinal toxicity in man are unknown. If
verapamil did enhance the gastrointestinal toxicity
of melphalan, the administration of melphalan with
verapamil or other anticalmodulin drugs should be
cautioned.
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